Alnylam Pharmaceuticals Inc (ALNY)

Add to Watchlists
Create an Alert
Quickflows
204.21 +0.39  +0.19% NASDAQ Oct 21, 16:00 204.21 0.00  0.00% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All ALNY News

News

View All Events

Events

Date Type Description
10/28/2021 Earnings Results Q3 2021 Earnings Results
10/28/2021 08:30 EST Earnings Calls Q3 2021 Earnings Call
08/03/2021 Earnings Results Q2 2021 Earnings Results
08/03/2021 08:30 EST Earnings Calls Q2 2021 Earnings Call
05/18/2021 10:30 EST AGM 2020 Annual General Meeting
04/29/2021 Earnings Results Q1 2021 Earnings Results
04/29/2021 08:30 EST Earnings Calls Q1 2021 Earnings Call
02/11/2021 Earnings Results Q4 2020 Earnings Results
02/11/2021 08:30 EST Earnings Calls Q4 2020 Earnings Call
11/05/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 687.53M
Total Expenses (TTM) 1.439B
Net Income (TTM) -886.68M

Balance Sheet View Statement

Total Assets (Quarterly) 3.509B
Total Liabilities (Quarterly) 2.656B
Shareholders Equity (Quarterly) 853.36M

Cash Flow Statement View Statement

Cash from Operations (TTM) -590.99M
Cash from Investing (TTM) 120.40M
Cash from Financing (TTM) 633.08M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
  • URL: https://www.alnylam.com
  • Investor Relations URL: https://investors.alnylam.com/
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Oct. 28, 2021
  • Last Earnings Release: Aug. 03, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 204.21
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
FIJYX Fidelity Advisor® Biotechnology Z 6.46%
FBIOX Fidelity® Select Biotechnology 3.53%
FBT First Trust NYSE Arca Biotech ETF 3.27%
VGHCX Vanguard Health Care Inv 2.52%
IBB iShares Biotechnology ETF 1.92%
FSPHX Fidelity® Select Health Care 1.81%
FXH First Trust Health Care AlphaDEX® ETF 1.69%
BMEZ BlackRock Health Sciences Trust II 1.33%
PRHSX T. Rowe Price Health Sciences 1.18%
FGCKX Fidelity® Growth Company K 1.12%
XBI SPDR® S&P Biotech ETF 0.83%
XT iShares Exponential Technologies ETF 0.74%

Comparables

Edit
LLY Eli Lilly and Co
BMRN Biomarin Pharmaceutical Inc
ESPR Esperion Therapeutics Inc
SAGE Sage Therapeutics Inc
CRVS Corvus Pharmaceuticals Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.